The Zhitong Finance App learned that long-term data from two phase 3 clinical trials of Johnson & Johnson (JNJ.US) showed that adult patients with Crohn's disease treated with Tremfya (guseciumab) had a clinical remission rate of up to 94% within three years.
According to reports, participants in the GALAXI2 and GALAXI3 trials first received Tremfya induction treatment, followed by maintenance treatment of 100 mg every 8 weeks or 200 mg every 4 weeks, respectively. The response rate was 94 per cent for the eight-week programme group and 91 per cent for the four-week programme group.
Furthermore, 52% of patients in the 8-week treatment group achieved endoscopic remission, compared to 61% of patients in the four-week treatment group.
Meanwhile, 88% of patients in both groups achieved 90-day corticosteroid-free clinical remission.
Additionally, Johnson & Johnson said the results of the Phase 3 FUZION study showed that Tremfya can achieve sustained fistula relief in specific Crohn's disease subgroups.
Overall, 28% of patients in the 8-week (q8w) treatment group, 27% of patients in the four-week (q4w) treatment group reached the composite endpoint of comprehensive fistula relief at week 24, compared to 10% in the placebo group.
However, among patients with high baseline lumbar disease activity, the remission rates in the q8w and q4w groups were 30% and 21%, respectively, and 0% in the placebo group.
Among patients treated with biologics previously, and in patients with or without proctitis at baseline, fistula relief was also significantly superior to the placebo group for those treated with Tremfya.